Ferric carboxymaltose for anemia in Crohn’s disease patients at a tertiary center: A retrospective observational cohort study

Figure 1 Hematological variables at baseline and after ferric carboxymaltose treatment. A: Median of hemoglobin; B: Hematocrit; C: Ferritin; D: Serum iron; E: Transferrin saturation. n = 25. Paired t-test with ^aP < 0.05; ^bP < 0.001.

Figure 2 Hematological variables at baseline and after the treatment with ferric carboxymaltose and ferric hydroxide sucrose. A: The median of hemoglobin; B: Hematocrit. n = 16. Paired t-test with ^bP < 0.001.

Figure 3 Suggested clinical management to the patient with Crohn’s disease and iron deficiency anemia. MCV: Mean corpuscular volume; HCM: Mean corpuscular hemoglobin; MCHC: Mean corpuscular hemoglobin concentration; STAT: Transferrin saturation.